Sign In
Buy ACOG
Alpha Cognition . Common Stock Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.410 |
| EPS actual | -$0.370 |
| EPS Surprise | 9.76% |
| Revenue estimate | 3.423M |
| Revenue actual | 3.534M |
| Revenue Surprise | 3.25% |
| Release date | Mar 26, 2026 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.300 |
| EPS Surprise | -11.11% |
| Revenue estimate | 3.198M |
| Revenue actual | 2.8M |
| Revenue Surprise | -12.43% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.430 |
| EPS actual | -$0.300 |
| EPS Surprise | 30.23% |
| Revenue estimate | 5.26M |
| Revenue actual | 2.841M |
| Revenue Surprise | -45.99% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.460 |
| EPS actual | -$0.650 |
| EPS Surprise | -41.30% |
| Revenue estimate | 4.155M |
| Revenue actual | 1.658M |
| Revenue Surprise | -60.11% |
Last 4 Quarters for Alpha Cognition . Common Stock
Below you can see how ACOG performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $8.00 |
| EPS estimate | -$0.460 |
| EPS actual | -$0.650 |
| EPS surprise | -41.30% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $9.90 |
| Aug 11, 2025 | $9.99 |
| Aug 12, 2025 | $9.70 |
| Aug 13, 2025 | $9.99 |
| Aug 14, 2025 | $8.00 |
| Aug 15, 2025 | $8.00 |
| Aug 18, 2025 | $8.45 |
| Aug 19, 2025 | $8.09 |
| Aug 20, 2025 | $8.00 |
| 4 days before | -19.19% |
| 4 days after | -0.0625% |
| On release day | 0% |
| Change in period | -19.24% |
| Release date | Nov 13, 2025 |
| Price on release | $5.87 |
| EPS estimate | -$0.430 |
| EPS actual | -$0.300 |
| EPS surprise | 30.23% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $5.72 |
| Nov 10, 2025 | $6.26 |
| Nov 11, 2025 | $6.00 |
| Nov 12, 2025 | $5.99 |
| Nov 13, 2025 | $5.87 |
| Nov 14, 2025 | $5.94 |
| Nov 17, 2025 | $5.90 |
| Nov 18, 2025 | $6.23 |
| Nov 19, 2025 | $5.92 |
| 4 days before | 2.62% |
| 4 days after | 0.85% |
| On release day | 1.19% |
| Change in period | 3.50% |
| Release date | Mar 26, 2026 |
| Price on release | $5.34 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.300 |
| EPS surprise | -11.11% |
| Date | Price |
|---|---|
| Mar 20, 2026 | $5.71 |
| Mar 23, 2026 | $5.80 |
| Mar 24, 2026 | $5.59 |
| Mar 25, 2026 | $5.32 |
| Mar 26, 2026 | $5.34 |
| Mar 27, 2026 | $5.08 |
| Mar 30, 2026 | $5.32 |
| Mar 31, 2026 | $5.49 |
| Apr 01, 2026 | $5.96 |
| 4 days before | -6.48% |
| 4 days after | 11.61% |
| On release day | -4.87% |
| Change in period | 4.38% |
| Release date | May 14, 2026 |
| Price on release | $5.68 |
| EPS estimate | -$0.410 |
| EPS actual | -$0.370 |
| EPS surprise | 9.76% |
| Date | Price |
|---|---|
| May 08, 2026 | $6.10 |
| May 11, 2026 | $5.95 |
| May 12, 2026 | $5.49 |
| May 13, 2026 | $5.95 |
| May 14, 2026 | $5.68 |
| May 15, 2026 | $6.02 |
| May 18, 2026 | $5.75 |
| May 19, 2026 | $5.80 |
| May 20, 2026 | $5.89 |
| 4 days before | -6.89% |
| 4 days after | 3.70% |
| On release day | 5.99% |
| Change in period | -3.44% |
Alpha Cognition . Common Stock Earnings Call Transcript Summary of Q1 2026
Alpha Cognition reported strong early commercial traction for ZUNVEYL in Q1 2026: net product revenue of $3.5M (+40% sequential vs. Q4 2025) with March the strongest month and April stronger than March. Prescription KPIs improved (bottles dispensed +23% vs. Q4; active prescribers +23% vs. year-end 2025) and the company is tracking toward ~2,000 prescribers in 2026. The commercial organization was scaled to a 60-person customer‑facing team. Alpha is investing deliberately in payer engagement and three real‑world/Phase IV programs (BEACON, CONVERGE, RESOLVE) to support prescriber confidence and payer coverage; BEACON enrollment will complete this quarter with top‑line data no later than early Q3 2026, and CONVERGE top line is expected in Q3. The company reported operating expense of ~$11.6M in Q1 and a net loss of ~$6.5M; cash was $54.2M at quarter end and the company remains debt free. Full‑year 2026 OpEx guidance of $54–$58M was reiterated, and management expects to reach operating profitability in 2027. Key near‑term catalysts: BEACON and CONVERGE topline data in Q3, sublingual PK data (Q3), ex‑U.S. regulatory milestones, and ongoing payer rollouts. Payer access is the main friction but management emphasizes strong underlying demand and high prior‑auth approval rates when supported by their team.
